View
7
Download
0
Category
Preview:
Citation preview
OUR IMMUNO-ONCOLOGY CLINICAL PIPELINE
Nektar Therapeutics is developing novel immunotherapies that harness key steps in the cancer immunity cycle1
Other cancersGenitourinary cancers
Advanced renal cell carcinoma
BEMPEG +NIVO
Muscle-invasive bladder cancer
BEMPEG + NIVO
Advanced bladder cancer
BEMPEG + NIVO
Advanced renal cell carcinoma
BEMPEG + NIVO + axitinib
Advanced melanoma
BEMPEG +NIVO
Adjuvant melanoma
BEMPEG + NIVO
Head and neck SCC
BEMPEG + Pfizer compounds
Metastatic prostate cancer
BEMPEG + Pfizer compounds
Advanced NSCLC
BEMPEG + pembrolizumab
Head and neck SCC
BEMPEG + VB10.NEO
Advanced solid tumors
NKTR-262 + BEMPEG
R/R NHL or multiple myeloma
NKTR-255 (IL-15RA)
PreclinicalProgramIndicationPartner Phase 1 Phase 2 Phase 3
BEMPEG, bempegaldesleukin (NKTR-214); FDA, U.S. Food and Drug Administration; IL-15RA, interleukin-15 receptor agonist; NHL, non-Hodgkin lymphoma; NIVO, nivolumab; NSCLC, non-small cell lung cancer; R/R, relapsed/refractory; SCC, squamous cell carcinoma.
1. Chen DS, Mellman I. Immunity 2013;39:1–10.
NCT03635983
NCT04052204
NCT04052204
NCT03138889
NCT03548467
NCT03435640
NCT04136756
NCT04410445
NCT03729245
NCT04209114
FDA Accelerated Approval registrational studyNCT03785925
NCT04540705
SCAN HERE to discover more about BEMPEG at Nektar.com
or email medicalaffairs@nektar.com
Registrational study
Registrational study
Registrational study
Registrational study
THE CANCER IMMUNITY CYCLE
Infiltration of T cells into tumor
Recognition of cancer cells by T cells
Killing of cancer cells
Priming, proliferation, activation
Release of cancer cell antigens
Cancer antigen presentation
Primes, proliferates, activates, and increases tumor-infiltrating lymphocytes;
increases PD-1 expression
BEMPEG (CD122-preferential agonist)5,6
Activates dendritic cell responseNKTR-262 (TLR 7/8 agonist)2–4
Key processes in the cancer immunity cycle must be activated, engaged, and promoted for an anticancer immune response to lead to the effective killing of cancer cells1
FOR EDUCATIONAL PURPOSES ONLY.These compounds and the combinations of agents and their uses have not been approved.
Nektar Therapeutics, 455 Mission Bay Boulevard South, San Francisco, California 94158. Copyright Nektar Therapeutics © 2020. All rights reserved.
BEMPEG, bempegaldesleukin (NKTR-214); IL, interleukin; NK, natural killer; PD-1, programmed death-1; TLR, toll-like receptor.
1. Chen DS, Mellman I. Immunity 2013;39:1–10. 2. Adams S. Immunotherapy 2009;1:949–964. 3. Kivimae S, et al. J Immunother Cancer 2017;5(Suppl 2):P275. 4. Lee M. Cancer Res 2018;78(13 Suppl):2755. 5. Charych DH, et al. Clin Cancer Res 2016;22:680–690. 6. Diab A, et al. J Immunother Cancer 2019;7(Suppl 1):O35. 7. Miyazaki T, et al. Cancer Res 2019;79(Suppl):3265. 8. Chou CK, et al. HemaSphere 2019;3(Suppl):PS1208.
NK cell
Tumor cells
CD8+ T cell (effector memory)
CD8+ T cell (central memory)
Dendritic cell
Tumor antigen
Stimulates and expands NK cells; promotes survival and expansion
of memory CD8+ T cells
NKTR-255 (IL-15 receptor agonist)7,8
Small-molecule therapy Cytokine therapy (IL-2 and IL-15)
Recommended